 |
|
|
| |
Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 10 mg Once Daily for 6 Days in Participants With Severe Renal Impairment and in Matched Control Participants With Normal Renal Function
|
| |
| |
EASL 2025 May 7-10 Amsterdam
Yehong Wang, Renee-Claude Mercier, Wildaliz Nieves, David Pan, Steve Tseng, Yuejiao Jiang, Ann Qin, Teckla Akinyi, Parag Kumar
Gilead Sciences, Inc., Foster City, CA, USA
|
| |
|
|
|
|
|
